Kura Oncology Inc (NASDAQ:KURA)

12.59
Delayed Data
As of May 20
 +0.46 / +3.79%
Today’s Change
10.41
Today|||52-Week Range
24.59
-10.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$839.9M

Company Description

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Contact Information

Kura Oncology, Inc.
12730 High Bluff Drive
San Diego California 92130
P:(858) 500-8800
Investor Relations:

Employees

Shareholders

Other institutional70.21%
Mutual fund holders28.06%
Individual stakeholders12.78%

Top Executives

Troy E. WilsonChairman, President, CEO & Chief Financial Officer
Kathleen FordChief Operating Officer
Mollie LeoniSenior Vice President-Clinical Development
Stephen DaleChief Medical Officer
Blake TomkinsonVice President-Clinical Development